摘要
目的探讨对CRF(慢性肾功能衰竭)尿毒症期患者分别开展HFHD(高通量血液透析)以及HD(常规血液透析)治疗后获得的临床效果。方法选择该院2013年1月—2017年1月收治的60例CRF尿毒症期患者作为实验对象;研究对象分组通过数字奇偶法完成;对照组(30例):临床开展慢性肾功能衰竭尿毒症期治疗工作期间,选择HD疗法施治;观察组(30例):临床开展慢性肾功能衰竭尿毒症期治疗工作期间,选择HFHD疗法施治;对CRF尿毒症期病症疗效、肾功能水平、Hb水平等以及透析并发症差异回顾性分析。结果同对照组CRF尿毒症期患者病症疗效(56.67%)比较,观察组CRF尿毒症期患者(96.67%)获得显著性提高(P<0.05)。结论临床在开展CRF尿毒症期治疗工作期间,合理应用HFHD方法加以施治,同HD疗效比较,在改善病症疗效、肾功能水平以及Hb水平等方面获得显著性效果,从而优化CRF尿毒症期患者的预后能力。
Objective To study the clinical curative effect of HFHD and HD in treatment of chronic renal failure uremia. Methods 60 cases of CRF uremia patients admitted and treated in our hospital from January 2013 to January2017 were selected and divided into two groups with 30 cases in each, the control group and the observation group were respectively treated with HD and HFHD, and the differences in the curative effects of CRF uremia diseases, renal function level, Hb level and dialysis complications were retrospectively analyzed. Results The curative effect in the control group was obviously improved compared with that in the observation group,（56.67% vs 96.67%）（P 〈0.05）.Conclusion The curative effects of rational application of HFHD in the development of CRF uremia diseases are more obvious than those of HD in improving the disease, renal function level and Hb level, thus optimizing the prognosis ability of CRF uremia patients.
出处
《系统医学》
2017年第16期51-53,共3页
Systems Medicine
